Discover a New Treatment Option for Some Patients with Triple-Class Refractory Multiple Myeloma

Explore a new therapy for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.

• Review safety, closing, and administration of the agent,
• Discuss efficacy data from a key clinical trial for this therapy,
• Address the challenges of treating some patients with triple-class refractory multiple myeloma